Larimar Therapeutics, Inc.
LRMR
$3.47
$0.3511.22%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -82.23% | 10.58% | -1.59% | -85.97% | 28.33% |
| Total Depreciation and Amortization | 1.15% | -1.14% | 14.29% | 4.05% | -14.94% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 7.50% | 26.99% | -12.98% | 491.41% | -58.75% |
| Change in Net Operating Assets | 222.51% | 231.70% | -71.64% | 161.82% | -231.77% |
| Cash from Operations | -48.36% | 26.97% | -21.66% | 11.13% | -75.48% |
| Capital Expenditure | -21.05% | 61.22% | 72.63% | -188.71% | 77.37% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 75.19% | 30.10% | -25.18% | -29.11% | 143.24% |
| Cash from Investing | 75.24% | 30.41% | -24.74% | -29.61% | 142.95% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | 20.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | 20.00% | 108.98% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 13,004.08% | 95.54% | -368.32% | -193.69% | 103.54% |